Multiple potential targets of opioids in the treatment of acute respiratory distress syndrome from COVID‐19

COVID‐19 can present with a variety of clinical features, ranging from asymptomatic or mild respiratory symptoms to fulminant acute respiratory distress syndrome (ARDS) depending on the host's immune responses and the extent of the associated pathologies. This implies that several measures need...

Descripción completa

Detalles Bibliográficos
Autores principales: Cismaru, Cosmin Andrei, Cismaru, Gabriel Laurentiu, Nabavi, Seyed Fazel, Ghanei, Mostafa, Burz, Claudia Cristina, Nabavi, Seyed Mohammad, Berindan Neagoe, Ioana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753383/
https://www.ncbi.nlm.nih.gov/pubmed/33211389
http://dx.doi.org/10.1111/jcmm.15927
Descripción
Sumario:COVID‐19 can present with a variety of clinical features, ranging from asymptomatic or mild respiratory symptoms to fulminant acute respiratory distress syndrome (ARDS) depending on the host's immune responses and the extent of the associated pathologies. This implies that several measures need to be taken to limit severely impairing symptoms caused by viral‐induced pathology in vital organs. Opioids are most exploited for their analgesic effects but their usage in the palliation of dyspnoea, immunomodulation and lysosomotropism may represent potential usages of opioids in COVID‐19. Here, we describe the mechanisms involved in each of these potential usages, highlighting the benefits of using opioids in the treatment of ARDS from SARS‐CoV‐2 infection.

Ejemplares similares